It’s not so much a question of alternate facilities (Baxter has many), it’s a question of capacity and ramping up production at other facilities. Then of course supply chain to get the production at alternate facilities where they need to go. And can the capacity of increased production at alternate facilities meet the need. They can not just create a new manufacturing facility. A LOT of qualification and validation needs to occur to get a new (novel) mfg site approved for any particular product (same with trying to get a product not normally manufactured at an existing manufacturing facility). Whether that be small molecule tablet/capsule or IV fluids or biologics. This is definitely going to cause some pain for a while and I’m sure several depts at Baxter are losing their mind trying to figure it all out. The regulatory folks are probably having daily conversations with FDA and the quality folks probably haven’t slept in a week.
__________________
Never try to teach a pig to fly. It wastes your time and annoys the pig.
|